Zacks Small Cap has inched its third-quarter 2025 earnings forecast for Longeveron Inc. higher, trimming the biotech’s expected loss to 26 cents a share. The research note, issued Aug. 14 by analyst B. Sorensen, offers a modest but notable vote of confidence in the Nasdaq-listed company.